Research programme: protein therapeutics - Talecris Biotherapeutics
Latest Information Update: 05 Apr 2011
Price :
$50 *
At a glance
- Originator Talecris Biotherapeutics
- Class Proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 14 Apr 2005 Preclinical trials in Undefined indication in USA (parenteral)